相关实验视频

Updated: Mar 12, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

一种针对泡细胞的脂质恢复策略稳定了脆弱的动脉样硬化斑块

Heng Li^1,2, Yusheng Qin^1,3, Jianhong Zhang¹

¹Department of Laboratory Medicine, Chongqing Center for Clinical Laboratory, Chongqing Academy of Medical Sciences, Chongqing General Hospital, School of Medicine, Chongqing University, Chongqing, 401147, China.

Bioactive materials

|March 11, 2026

概括

研究人员开发了一个新的纳米平台,OPN-HMCN@MLT,以准和治疗脆弱的动脉样硬化斑块. 这种创新疗法通过向药物输送和分子成像促进斑块回归并增强稳定性.

科学领域:

心血管研究研究心血管研究
纳米医学是一种纳米医学.
生物材料是一种生物材料.

背景情况:

动脉样硬化治疗在逆转脆弱的斑块方面面临着挑战.
现有的疗法在斑块回归方面有效性有限.
向纳米医学为先进的动脉样硬化管理提供了潜力.

研究的目的:

开发一种新的纳米平台,用于针对性治疗和脆弱动脉样硬化斑块的成像.
调查OPN-HMCN@MLT在促进斑块回归和稳定的有效性.
建立一个以治疗为中心的纳米医学策略,用于精确干预.

主要方法:

开发了OPN-HMCN@MLT纳米平台,该纳米平台结合了氨酸,OPN结合和氨酸修饰的半孔碳.
利用斑块微环境 (酸性pH,HAase,OPN) 进行级联反应的药物释放.
无标签的光声学 (PA) 成像用于斑块可视化和监测.
在体内研究,以评估治疗疗效和全身毒性.

主要成果:

OPN-HMCN@MLT证明了精确的斑块向和增强的PA成像信号.
在体内研究表明,抑制了斑块的进展和已确定的病变的回归.
治疗效果包括减少泡细胞积累,改善脂质新陈代谢和增强斑块稳定性.
没有观察到可检测的全身毒性.

结论:

OPN-HMCN@MLT有效地向脆弱的动脉样硬化斑块,使治疗干预和分子成像成为可能.
纳米平台通过恢复脂质和改善代谢概况来促进斑块回归.
这一策略为管理先进动脉样硬化提供了显著的翻译潜力,具有精确和纵向监测.

关键词:

脂质性消化 (Lipophagy) 是一种消化方式.黑色素是什么黑色素是什么黑色素是什么半孔碳是半孔碳的一种.照片声学成像成像技术易受伤害的动脉样硬化斑块

更多相关视频

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

相关概念视频

Inflammation

Inflammation

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...